ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > class war

<< Previous

Bullboard Posts

Next >>

Comment by M101on Feb 21, 2022 11:55am

165 Views

Post# 34447884

RE:RE:RE:RE:class war

Let's not confuse insight with opinion.

Your question got me to browse some of the plentiful pundit opinions on pharma M&A trends, but I came away learning nothing except that too much money chasing limited opportunities leads to share buybacks rather than pipeline building. And given that I hope our directors will shoot for the moon when the first offer finally drops and settle for nothnig short of a bidding war.

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks